Du Tingting, Huang Yuchai, Lv Yongman, Yuan Gang
Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Branch of National Clinical Research Center for Metabolic Diseases, Wuhan, China.
J Gastroenterol. 2025 Mar;60(3):315-327. doi: 10.1007/s00535-024-02184-x. Epub 2024 Nov 27.
Data regarding the prevalence of hepatic fibrotic burden across the spectrum of hypothyroidism are scarce. Hence, we aimed to evaluate the prevalence of liver fibrotic burden across the spectrum of hypothyroidism.
30,091 individuals who attended a Health Management Centre between 2019 and 2021 were cross-sectionally analyzed. Participants were categorized as having strict-normal thyroid function, low-normal thyroid function, subclinical hypothyroidism, and overt hypothyroidism. Hepatic fibrosis was assessed by vibration-controlled transient elastography (VCTE). Significant and advanced fibrosis were defined as liver stiffness measurement in VCTE of 8.1-9.6 and 9.7-13.5 kPa, respectively.
Among both men and women, low-normal thyroid function group, subclinical hypothyroidism group, and overt hypothyroidism group all have more liver fibrosis present, including mild fibrosis, significant fibrosis, advanced fibrosis, and cirrhosis, than the strict-normal thyroid function group. The low-normal thyroid function group have the similar liver fibrotic burden to the subclinical hypothyroidism group. The highest liver fibrotic burden was noted in the overt hypothyroidism group. Both significant and advanced liver fibrosis were significantly associated with low-normal thyroid function, subclinical hypothyroidism, and overt hypothyroidism in both men and women.
Liver fibrotic burden are highly prevalent in subjects with overt hypothyroidism. Moreover, fibrotic burden increased across the spectrum of hypothyroidism even within the low normal thyroid function. These results suggested that screening for liver fibrosis in patients with hypothyroidism is necessary.
关于甲状腺功能减退症全谱范围内肝纤维化负担患病率的数据稀缺。因此,我们旨在评估甲状腺功能减退症全谱范围内肝纤维化负担的患病率。
对2019年至2021年间前往健康管理中心的30091名个体进行横断面分析。参与者被分类为具有严格正常甲状腺功能、低正常甲状腺功能、亚临床甲状腺功能减退症和显性甲状腺功能减退症。通过振动控制瞬时弹性成像(VCTE)评估肝纤维化。显著纤维化和进展性纤维化分别定义为VCTE中肝脏硬度测量值为8.1 - 9.6 kPa和9.7 - 13.5 kPa。
在男性和女性中,低正常甲状腺功能组、亚临床甲状腺功能减退症组和显性甲状腺功能减退症组出现的肝纤维化,包括轻度纤维化、显著纤维化、进展性纤维化和肝硬化,均比严格正常甲状腺功能组更多。低正常甲状腺功能组的肝纤维化负担与亚临床甲状腺功能减退症组相似。显性甲状腺功能减退症组的肝纤维化负担最高。男性和女性中,显著和进展性肝纤维化均与低正常甲状腺功能、亚临床甲状腺功能减退症和显性甲状腺功能减退症显著相关。
显性甲状腺功能减退症患者中肝纤维化负担非常普遍。此外,即使在低正常甲状腺功能范围内,甲状腺功能减退症全谱范围内的纤维化负担也会增加。这些结果表明,对甲状腺功能减退症患者进行肝纤维化筛查是必要的。